Drugs / Novolimus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05033964 | Dec 2021 → Dec 2022 overdue | coronary artery disorder | Elixir Medical Corporation | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04483791 Background | Sep 2020 → Dec 2022 | coronary artery disorder | Elixir Medical Corporation | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novolimus | “The DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2 NECSS; DESyne X2) is loaded with Novolimus” NCT05033964 ↗ |